Description

Description

Glem-Lin 10/5mg is a combination prescription medicine manufactured by NABIQASIM Industries, formulated with two active ingredients: Empagliflozin 10mg and Linagliptin 5mg. Empagliflozin belongs to a class of medicines called SGLT2 inhibitors, which work by helping the kidneys remove excess glucose from the body through urine. Linagliptin, a DPP-4 inhibitor, works by increasing the levels of incretin hormones that stimulate insulin release and reduce glucose production in the liver. Together, these two mechanisms provide complementary, dual-action blood sugar control, making Glem-Lin a convenient option for patients who require more comprehensive glycemic management.

Ingredients

Each film-coated tablet contains Empagliflozin 10mg and Linagliptin 5mg, combined with pharmaceutical-grade excipients that support tablet stability, consistent absorption, and shelf life.

Dosage Form

Glem-Lin is available as an oral film-coated tablet, packaged in a strip of 14 tablets for structured daily use.

Uses

Glem-Lin 10/5mg is prescribed to:

• Improve blood glucose control in adults with type 2 diabetes mellitus
• Provide combination therapy for patients not adequately controlled on a single agent
• Support glycemic management alongside diet and exercise
• Reduce the treatment burden of taking two separate diabetes medicines

Your physician will determine suitability based on your kidney function, blood sugar levels, and overall treatment plan.

How To Use

Take Glem-Lin exactly as prescribed by your doctor, typically once daily in the morning, with or without food. Swallow the tablet whole with a glass of water; do not crush or chew it. Maintain a consistent daily routine and follow any dietary or lifestyle recommendations provided by your healthcare provider. Do not adjust your dose or discontinue the medicine without consulting your doctor, as this may affect blood sugar control.

Side Effects

Common side effects may include urinary tract infections, genital yeast infections, increased urination, or mild dehydration due to the glucose-elimination effect of Empagliflozin. Some patients may experience nasopharyngitis, headache, or mild gastrointestinal discomfort linked to Linagliptin. Less commonly, patients may notice low blood pressure, joint pain, or signs of low blood sugar (hypoglycemia) if combined with other diabetes medicines. Seek immediate medical attention if you experience symptoms of ketoacidosis, severe dehydration, or an allergic reaction.

Pregnancy & Breastfeeding

Glem-Lin is generally not recommended during pregnancy, as its effects on fetal development have not been well studied, and alternative treatments are usually preferred. It is not known whether these ingredients pass into breast milk, so breastfeeding mothers should consult their doctor before use to ensure infant safety.

Storage Instructions

Store Glem-Lin tablets in a cool, dry place away from direct sunlight and moisture, at a temperature below 30°C. Keep tablets in their original blister packaging and store out of reach of children.

FAQs

Q: How is Glem-Lin different from taking Empagliflozin and Linagliptin separately?
A: Glem-Lin combines both medicines into a single tablet, simplifying your daily dosing routine while providing the same dual-action benefit.

Q: Can this medicine cause low blood sugar on its own?
A: On its own, the risk is low, but combining it with insulin or sulfonylureas may increase the risk of hypoglycemia.

Q: Should I drink more water while taking Glem-Lin?
A: Yes, staying well hydrated is recommended, as Empagliflozin increases urination and glucose elimination.

Q: Is Glem-Lin suitable for patients with kidney problems?
A: Your doctor will assess your kidney function before prescribing, as dosing may need adjustment in impaired kidney function.

Disclaimer

Always use this medicine strictly according to your doctor’s instructions and prescribed dosage.